ALK and melanoma: Crizotinib is a multi-targeted tyrosine kinase inhibitor, targeting ALK, c-Met, and ROS1, and FDA approved for the treatment of non-small cell lung cancer (NSCLC) patients with ALK rearranged mutations and melanoma patients (15–17).